glp-1 agonists for diabetes glp-1_analogs [TUSOM GLP-1 receptor agonists (GLP-1RAs): cardiovascular

A pivotal 2021 clinical study of more than 1,900 adults, known as the STEP 1 trial, laid the groundwork for the use of these drugs as a treatment for weight loss

10.3390/biomedicines13051260 63 JerlhagE

Mild to moderate transient gastrointestinal side effects were the most frequently reported adverse events associated with tirzepatide treatment (nausea 12%18% vs

In individuals with type 2 diabetes and NAFLD, macrovascular complications are a leading cause of morbidity and mortality [25]

Clinical Efficacy: Evidence from Major Trials Weight Loss Outcomes in Non-Diabetic Patients The clinical efficacy of GLP-1 agonists for weight loss in non-diabetic patients has been demonstrated across multiple large-scale randomized controlled trials

GLP-1 RAs have demonstrated benefits in coronary artery disease, heart failure, blood pressure, and atrial fibrillation irrespective of type 2 diabetes mellitus status, with new possible applications in peripheral arterial disease